Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE.

Kileel EM, Malvestutto CD, Zanni MV, Davies-Smith E, Fichtenbaum CJ, Lake JE, Lo J, Aberg JA, Martinez E, Patel K, Bloomfield GS, Chu SM, Awwad A, Diggs MR, Lu AB, Bares SH, Berrner D, Smieja M, Okeke NL, Kumar P, João E, Currier JS, Lu MT, Fox MP, Brennan AT, Douglas PS, Grinspoon SK, Ribaudo HJ.

Open source

DOI: 10.1016/s2352-3018(25)00354-6
Published: 2026-03-27
Container: Lancet HIV
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2352-3018-25-00354-6,
  title = {Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE.},
  author = {Kileel EM and  Malvestutto CD and  Zanni MV and  Davies-Smith E and  Fichtenbaum CJ and  Lake JE and  Lo J and  Aberg JA and  Martinez E and  Patel K and  Bloomfield GS and  Chu SM and  Awwad A and  Diggs MR and  Lu AB and  Bares SH and  Berrner D and  Smieja M and  Okeke NL and  Kumar P and  João E and  Currier JS and  Lu MT and  Fox MP and  Brennan AT and  Douglas PS and  Grinspoon SK and  Ribaudo HJ.},
  year = {2026},
  journal = {Lancet HIV},
  doi = {10.1016/s2352-3018(25)00354-6},
  url = {https://doi.org/10.1016/s2352-3018(25)00354-6}
}

RIS

TY  - JOUR
TI  - Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE.
AU  - Kileel EM
AU  -  Malvestutto CD
AU  -  Zanni MV
AU  -  Davies-Smith E
AU  -  Fichtenbaum CJ
AU  -  Lake JE
AU  -  Lo J
AU  -  Aberg JA
AU  -  Martinez E
AU  -  Patel K
AU  -  Bloomfield GS
AU  -  Chu SM
AU  -  Awwad A
AU  -  Diggs MR
AU  -  Lu AB
AU  -  Bares SH
AU  -  Berrner D
AU  -  Smieja M
AU  -  Okeke NL
AU  -  Kumar P
AU  -  João E
AU  -  Currier JS
AU  -  Lu MT
AU  -  Fox MP
AU  -  Brennan AT
AU  -  Douglas PS
AU  -  Grinspoon SK
AU  -  Ribaudo HJ.
PY  - 2026
JO  - Lancet HIV
DO  - 10.1016/s2352-3018(25)00354-6
UR  - https://doi.org/10.1016/s2352-3018(25)00354-6
ER  -

APA

EM, K., CD, M., MV, Z., E, D., CJ, F., JE, L., J, L., JA, A., E, M., K, P., GS, B., SM, C., A, A., MR, D., AB, L., SH, B., D, B., M, S., NL, O., P, K., E, J., JS, C., MT, L., MP, F., AT, B., PS, D., SK, G., & HJ., R. (2026). Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE.. Lancet HIV. https://doi.org/10.1016/s2352-3018(25)00354-6

Source records

europe-pmc · retrieved 2026-09-26T20:26:51.961Z